|
PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. We attack these challenges with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions.
PolyMedix focuses on serious, life threatening, acute disorders which are also significant market opportunities. Using our proprietary computational drug design technology, we have created novel antibiotic compounds and heptagonists. Our lead candidates in each of these programs, i.v. antibiotic candidate PMX-30063 and the anticoagulant antagonist product candidate PMX-60056, are
currently in human clinical trials.
PMX-30063 began phase I clinical
trials in August, 2008 and PMX-60056
began clinical trials in September
2008.
PolyMedix is a publicly traded company (OTC BB:PYMX).
November 17, 2009
PolyMedix Completes $20.7 Million Equity Financing
Funds To Be Used To Continue Development of Two Drug Candidates Into Phase 2 Human Clinical Trials
Radnor, PA (November 17, 2009) – PolyMedix Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a public offering of units for aggregate gross proceeds of $20.7 million. The units, which were priced at $1.00 per unit, consist of one share of PolyMedix common stock and one five year warrant to purchase 0.30 of a share of PolyMedix common stock at $1.25 per share. Commencing six months after the closing and subject to certain volume requirements, the warrants may be called by the Company in the event that the 20-day volume weighted average price for the Company’s common stock is greater than or equal to $3.75. Merriman Curhan Ford (Nasdaq: MERR) acted as lead placement agent in this offering with Boenning & Scattergood, Inc. and Noble Financial Capital Markets serving as co-placement agents. Fordham Financial Management, Inc. acted as a selected dealer in connection with the offering. »read more
|
|
|
November 11, 2009
PolyMedix Announces Up To $21 Million Public Equity Offering
Funds To Be Used To Continue Development of Two Drug Candidates Into Phase 2 Human Clinical Trials
Radnor, PA (November 11, 2009) – PolyMedix Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today the pricing of a registered public offering of up to 21,000,000 units consisting of shares and warrants for $1.00 per unit, or a total of up to $21 million in gross proceeds. The units consist of one share of PolyMedix common stock and a five year warrant to purchase 0.30 shares of PolyMedix common stock at $1.25 per share. The units will not be certificated and the shares and warrants will be immediately separable and transferable upon issuance. Merriman Curhan Ford (Nasdaq: MERR) acted as lead placement agent in this offering with Boenning & Scattergood, Inc. and Noble Financial Capital Markets serving as co-placement agents. Fordham Financial Management, Inc. acted as a selected dealer in the offering. »read more
|
|
